Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

77.88EUR
12:45pm BST
Change (% chg)

€0.66 (+0.85%)
Prev Close
€77.22
Open
€77.18
Day's High
€78.12
Day's Low
€77.18
Volume
67,902
Avg. Vol
342,063
52-wk High
€81.48
52-wk Low
€58.66

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €11,689.79
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.34

Financials

  UCB.BR Industry Sector
P/E (TTM): 17.05 30.93 32.76
EPS (TTM): 3.53 -- --
ROI: 8.89 15.07 14.61
ROE: 12.31 16.59 16.33

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

13 Aug 2018

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

27 Apr 2018

BRIEF-UCB Q1 Revenue Down At 1.07 Billion Euros

* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION

25 Apr 2018

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

20 Apr 2018

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

05 Apr 2018

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

03 Apr 2018

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

30 Mar 2018

Earnings vs. Estimates